Genitourinary Cancers

FDA Approves Pembrolizumab for BCG-Unresponsive NMIBC
February 13, 2020

The FDA  approved pembrolizumab (Keytruda) for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or chose to not undergo cystectomy.

Study Shows Efficacy of Single-Cycle BEP in Preventing Testicular Cancer Recurrence
January 08, 2020

Results of this phase III trial could change the current standard of care for treating nonseminomatous or combined germ cell tumors of the testis.

Phase III JAVELIN Bladder 100 Meets Primary Endpoint of Overall Survival
January 06, 2020

The study found that patients who were randomized to receive avelumab and best supportive care lived significantly longer than those who only received best supportive care.